Tirzepatide Doubles Semaglutide's 15% Loss Rate in Rheumatology
A real-world RISE registry study of 60,000+ rheumatology patients finds tirzepatide users nearly twice as likely as semaglutide users to lose 15% of body weight.
May 22, 2026 · 3 min read
A new real-world analysis published in ACR Open Rheumatology finds that both tirzepatide and semaglutide help patients in rheumatology care lose meaningful weight — but tirzepatide users were nearly twice as likely to hit the 15% body weight loss threshold, according to data from more than 60,000 patients in a national US registry.
The Study
Researchers drew on the ACR's RISE registry (Rheumatology Informatics System for Effectiveness), which captures data from US rheumatology practices. The dataset included 60,198 adults with rheumatic and musculoskeletal diseases (RMDs) who received semaglutide or tirzepatide between 2018 and 2024 — one of the largest real-world GLP-1 datasets in a rheumatology-specific population.
The primary comparison looked at 1-year weight loss outcomes. At 1 year:
- Tirzepatide users were ~50% more likely to lose at least 5% of body weight than semaglutide users (adjusted odds ratio 1.46; 95% CI 1.36–1.57)
- Tirzepatide users had nearly double the odds of losing at least 15% of body weight (adjusted OR 1.94)
- Both drugs were associated with meaningful weight loss; greater reductions were observed in patients without type 2 diabetes
The analysis adjusted for baseline characteristics, which is important in any observational comparison between two drugs that are prescribed to different patient profiles in practice.
Why Rheumatology Patients Are a Distinct Population
Patients with RMDs — conditions including rheumatoid arthritis, psoriatic arthritis, lupus, osteoarthritis, and gout — face a specific challenge when it comes to weight management: many have pain, fatigue, or physical limitations that make exercise-based approaches more difficult than for the general obesity population.
This makes pharmacological weight management particularly relevant. At the same time, some RMDs (especially inflammatory arthritis) have their own metabolic profile — systemic inflammation, steroid use, and altered cytokine signaling — that could affect how GLP-1 drugs perform. The RISE registry provides a look at how these drugs actually work in clinical practice for this population, not in a trial setting where patients are typically healthier than those seen in routine care.
Weight loss matters in RMD management beyond aesthetics. Obesity drives disease activity in conditions like osteoarthritis (mechanical loading), psoriatic arthritis (inflammatory linkage), and gout (uric acid metabolism). Meaningful weight reduction has downstream effects on joint burden, flare frequency, and medication response.
Caveats on an Observational Study
The adjusted OR difference between tirzepatide and semaglutide in this dataset is real and statistically significant, but carries the standard caveats of real-world observational data:
Confounding by indication is the key concern. Tirzepatide is a newer, higher-efficacy agent that may have been preferentially prescribed to patients with more obesity-focused management goals, or to patients who had previously tried and not responded to semaglutide. If the tirzepatide-treated group had higher baseline motivation or more obesity-focused follow-up, that would inflate the apparent advantage.
Dose and duration differences can't be fully standardized across an observational registry the way they are in an RCT.
The SURMOUNT-5 trial, which directly randomized patients to tirzepatide vs. semaglutide for weight management, showed tirzepatide achieving 20.2% mean weight loss vs. 13.7% for semaglutide — a head-to-head RCT result that validates the direction of this observational finding in the general population. The RISE registry extends that signal to rheumatology patients specifically, where it hadn't been characterized before.
What to Watch
Whether tirzepatide's weight loss advantage in rheumatology patients translates to measurable differences in disease outcomes — joint damage, flare rates, remission rates — is the next question. The RISE registry data focuses on weight; linking it to rheumatological endpoints requires additional follow-up analysis. The researchers indicated ongoing work on disease activity outcomes.
Sources
Sources